Sort
48,018 grants matching “immunotherapy”
Scientific Core B
$377,472Holden T. Maecker · Stanford University · U19 · FY2015 · AI
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHN
$377,462Albert B Deleo · University Of Pittsburgh At Pittsburgh · P50 · FY2007 · CA
Administrative Core
$377,458James R. Heath · Institute For Systems Biology · U54 · FY2024 · CA
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
$377,457Aimee S Payne · Columbia University Health Sciences · R01 · FY2025 · AR
Characterization of the interaction between inflammation and cancer progression
$377,448Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2020 · CA
Rewiring the myeloid cell response to adjuvants to improve tumor control
$377,438Michael James Gough · Providence Portland Medical Center · R01 · FY2021 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2016 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2017 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$377,438Marka Crittenden · Providence Portland Medical Center · R01 · FY2018 · CA
Rewiring the myeloid cell response to adjuvants to improve tumor control
$377,438Michael James Gough · Providence Portland Medical Center · R01 · FY2020 · CA
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy
$377,428David G Denardo · Washington University · P50 · FY2025 · CA
An innovative hemoperfusion nanotrap for sepsis treatment.
$377,423Juntao Luo · Upstate Medical University · R01 · FY2021 · GM
Project 1: Promoting Graft-versus-Tumor Effects in the Bone Marrow
$377,415Geoffrey Roger Hill · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA
Improving T-cell therapies for neuroblastoma
$377,399Gianpietro Dotti · Baylor College Of Medicine · R01 · FY2012 · CA
DPT-1 / TrialNet
$377,395University Of Colorado Denver · U01 · FY2003 · DK
Career Development in Pediatric and Medical Oncology
$377,387Irwin Bernstein · Fred Hutchinson Cancer Research Center · K12 · FY2011 · CA
Project 2: Dual Targeting of B7-H3 in mCRPC
$377,386Kenneth J. Pienta · Johns Hopkins University · P50 · FY2025 · CA
Augmentation of Immune Response to Head & Neck Squamous Cell Carcinoma via Phosp
$377,385Ivan M Borrello · Johns Hopkins University · P50 · FY2015 · DE
Monoclonal Antibodies for the Study of P. carinii
$377,375Francis Gigliotti · University Of Rochester · R01 · FY2006 · AI
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$377,327Fumito Ito · University Of Southern California · R01 · FY2024 · CA
Evaluation of image-guided, conformal, high-dose intraoperative radiation therapy (Precision Breast IORT) for early stage breast cancer
$377,273Shayna Lefrak Showalter · University Of Virginia · R01 · FY2021 · CA
Training In Cell and Gene Therapy
$377,268Helen E Heslop · Baylor College Of Medicine · T32 · FY2020 · HL
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.
$377,228Silvia C Formenti · New York University School Of Medicine · R01 · FY2012 · CA
CD8 T Cell Replicative Senescence & HIV Disease
$377,173Rita Brickman Effros · University Of California Los Angeles · R01 · FY2006 · AI